Cancer chronotherapeutics: Experimental, theoretical, and clinical aspects

Handbook of Experimental Pharmacology

Volumn 217, Issue , 2013, Pages 261-288

  Ortiz Tudela, E ^a,b   Mteyrek, A ^a,c   Ballesta, A ^a,c,d   Innominato, P F ^a,c   Levi, F ^a,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITY OF MURCIA   (Spain)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INRIA ROCQUENCOURT   (France)

Author keywords

Cancer; Chronoefficacy; Chronotherapy; Chronotolerance; Circadian rhythms; Clinical trials; Mathematical models; Survival

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TRANSCRIPTION FACTOR CLOCK; ANTINEOPLASTIC AGENT;

ACTIMETRY; ARTICLE; BODY TEMPERATURE MONITORING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL EFFECTIVENESS; CLOCK GENE; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; GENE FUNCTION; GENE IDENTIFICATION; HORMONE ACTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS OPTIMIZATION; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; ANIMAL; CELL CYCLE; NEOPLASM; PATHOLOGY; PERSONALIZED MEDICINE; REVIEW; THEORETICAL MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; CIRCADIAN RHYTHM; DRUG CHRONOTHERAPY; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, THEORETICAL; NEOPLASMS;

MLCS; MLOWN;

EID: 84880398723     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25950-0_11     Document Type: Article

References (151)

1. Abercrombie HC, Giese-Davis J, Sephton S et al (2004) Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 29(8):1082-92
2. Adan A, Natale V (2002) Gender differences in morningness-eveningness preference. Chronobiol Int 19(4):709-20
3. Ahowesso C, Piccolo E, Li XM et al (2010) Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett 192(3):395-401
4. Ahowesso C, Li XM, Zampera S et al (2011) Sex and dosing-time dependencies in irinotecaninduced circadian disruption. Chronobiol Int 28(5):458-70
5. Altinok A, Levi F, Goldbeter A (2007) A cell cycle automaton model for probing circadian patterns of anticancer drug delivery. Adv Drug Deliv Rev 59:1036-53
6. Ancoli-Israel S, Moore PJ, Jones V (2001) The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care 10(4):245-55
7. Ancoli-Israel S, Cole R, Alessi C (2003) The role of actigraphy in the study of sleep and circadian rhythms. Sleep 26(3):342-92
8. Ancoli-Israel S, Rissling M, Neikrug A et al (2011) Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer 20(6):1211-9
9. Antoch MP, Kondratov RV (2013) Pharmacological modulators of the circadian clock as potential therapeutic drugs: Focus on genotoxic/anticancer therapy. In: Kramer A, Merrow M (eds) Circadian clocks, vol 217, Handbook of experimental pharmacology. Springer, Heidelberg
10. Ballesta A, Dulong S, Abbara C et al (2011) A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol 7(9): e1002143
11. Barsevick A, Frost M, Zwinderman A et al (2010) I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 19(10):1419-27
12. Basdevant C, Clairambault J, Levi F (2005) Optimisation of time-scheduled regimen for anticancer drug infusion. ESAIM Math Model Numer Anal 39(6):1069-1086
13. Beau J, Innominato PF, Carnino S, Levi F (2009) An implanted device for the adjustment of cancer chronotherapeutics to the patient's circadian timing system. In: XI Congress of the European Biological Rhythms Society, Strasbourg, France, 22-28 Aug 2009
14. Berger AM, Farr LA, Kuhn BR et al (2007) Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage 33(4):398-409
15. Berger AM, Grem JL, Visovsky C et al (2010) Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. Oncol Nurs Forum 37(6):E359-69
16. Bernard S, Cajavec Bernard B et al (2010) Tumour growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput Biol 3:1000712
17. Billy F, Clairambault J, Fercoq O (2012) Optimisation of cancer drug treatments using cell population dynamics. In: Friedman A, Kashdan E, Ledzewicz U, Schattler H (eds) Mathematical methods and models in biomedicine. Springer, New York, pp 257-299
18. Bjarnason GA, Jordan RC, Wood PA et al (2001) Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 158(5):1793-801
19. Bjarnason GA, Mackenzie RG, Nabid A et al (2009) Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys 73(1):166-72
20. Bordyugov G, Westermark PO, Korencic A, Bernard S, Herzel H (2013) Mathematical modeling in chronobiology. In: Kramer A, Merrow M (eds) Circadian clocks, vol 217, Handbook of experimental pharmacology. Springer, Heidelberg
21. Bouchahda M, Adam R, Giacchetti S et al (2009) Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 115(21):4990-9
22. Bouchahda M, Levi F, Adam R et al (2011) Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer 47(18):2681-90
23. Boughattas NA, Levi F, Fournier C et al (1989) Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1) oxalatoplatinum(II) in mice. Cancer Res 49(12):3362-8
24. Buhr ED, Takahashi JS (2013) Molecular components of the mammalian circadian clock. In: Kramer A, Merrow M (eds) Circadian clocks, vol 217, Handbook of experimental pharmacology. Springer, Heidelberg
25. Buhr ED, Yoo SH, Takahashi JS (2010) Temperature as a universal resetting cue for mammalian circadian oscillators. Science 330(6002):379-85
26. Calogiuri G, Weydahl A, Carandente F (2011) Methodological issues for studying the rest-activity cycle and sleep disturbances: a chronobiological approach using actigraphy data. Biol Res Nurs 15(1):5-12
27. Calzone L, Soliman S (2006) Coupling the cell cycle and the circadian cycle. INRIA internal research report #5835. INRIA, Rocquencourt
28. Caussanel JP, Levi F, Brienza S et al (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82(12):1046-50
29. Cermakian N, Boivin DB (2003) A molecular perspective of human circadian rhythm disorders. Brain Res Brain Res Rev 42:204-20
30. Chen ST, Choo KB, Hou MF et al (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26(7):1241-6
31. Chu LW, Zhu Y, Yu K et al (2008) Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis 4:342-8
32. Clairambault J (2007) Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance. Adv Drug Deliv Rev 59(9-10):1054-68
33. Clow A, Hucklebridge F, Thorn L (2010) The cortisol awakening response in context. Int Rev Neurobiol 93:153-75
34. Costa MJ, Finkenstadt BF, Gould PD et al (2013) Inference on periodicity of circadian time series. Biostatistics (in press)
35. de Gramont A, Vignoud J, Tournigand C et al (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33(2):214-9
36. de Maria E, Fages F, Soliman S (2009) INRIA research report, 7064. INRIA, Rocquencourt
37. Duffy JF, Dijk DJ, Hall EF et al (1999) Relationship of endogenous circadian melatonin and temperature rhythms to self-reported preference for morning or evening activity in young and older people. J Invest Med 47:141-50
38. Duffy JF, Cain SW, Chang AM et al (2011) Sex difference in the near-24-hour intrinsic period of the human circadian timing system. Proc Natl Acad Sci USA 108(Suppl 3):15602-8
39. Eisele L, Prinz R, Klein-Hitpass L et al (2009) Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol 83(4):320-7
40. Etienne-Grimaldi MC, Cardot JM, Francois E et al (2008) Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. Clin Pharmacol Ther 83(3):413-5
41. Filipski E, King VM, Li X et al (2002) Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 94(9):690-7
42. Filipski E, Delaunay F, King VM et al (2004) Effects of chronic jet lag on tumor progression in mice. Cancer Res 64(21):7879-85
43. Filipski E, Innominato PF, Wu M et al (2005) Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst 97(7):507-17
44. Filipski E, Li XM, Levi F (2006) Disruption of circadian coordination and malignant growth. Cancer Causes Control 17(4):509-14
45. Focan C, Denis B, Kreutz F et al (1995) Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. J Infus Chemother 5(3 Suppl 1):148-52
46. Foley C, Mackey MC (2009) Dynamic hematological disease: a review. J Math Biol 58(1-2): 285-322
47. Forger DB, Dean DA 2nd, Gurdziel K et al (2003) Development and validation of computational models for mammalian circadian oscillators. OMICS 4:387-400
48. Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3(5):350-61
49. Fu L, Pelicano H, Liu J et al (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111(1):41-50
50. Gerard C, Goldbeter A (2009) Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle. Proc Natl Acad Sci USA 106(51):21643-8
51. Gery S, Gombart AF, Yi WS et al (2005) Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106(8):2827-36
52. Gery S, Komatsu N, Baldjyan L et al (2006) The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22(3):375-82
53. Giacchetti S, Bjarnason G, Garufi C et al (2006) European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as firstline chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24(22):3562-9
54. Giacchetti S, Dugue PA, Innominato PF et al (2012) Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol 23(12):3110-3116
55. Goodwin BC (1965) Oscillatory behavior in enzymatic control processes. In: Weber G (ed) Advances in enzyme regulation, vol 3. Pergamon, Oxford, pp 425-438
56. Gorbacheva VY, Kondratov RV, Zhang R et al (2005) Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci USA 102(9):3407-12
57. Granda TG, Liu XH, Smaaland R et al (2005) Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 19(2):304-6
58. Grutsch JF, Wood PA, Du-Quiton J et al (2011) Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer. J Circadian Rhythms 9:4
59. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-74
60. Hardeland R, Madrid JA, Tan DX et al (2011) Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res. doi:10.1111/j.1600-079X.2011.00934.x
61. Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4(8):649-61
62. Haus E (2002) Chronobiology of the mammalian response to ionizing radiation. Potential applications in oncology. Chronobiol Int 19(1):77-100
63. Hoffman AE, Zheng T, Stevens RG et al (2009) Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res 69(8):3605-13
64. Hrushesky WJ (1985) Circadian timing of cancer chemotherapy. Science 228(4695):73-5
65. Huang W, Ramsey KM, Marcheva B et al (2011) Circadian rhythms, sleep, and metabolism. J Clin Invest 121(6):2133-41
66. Hunt T, Sassone-Corsi P et al (2007) Riding tandem: circadian clocks and the cell cycle. Cell 129(3):461-4
67. Iacobelli S, Innominato PF, Piantelli M et al (2008) Tumor clock protein PER2 as a determinant of survival in patients receiving oxaliplatin-5-FU- leucovirin as first-line chemotherapy for metastatic colorectal cancer. In: 44th Annual meeting of the American Society of Clinical Oncology, Chicago, IL, USA
68. Innominato PF, Focan C, Gorlia T et al (2009) Chronotherapy Group of the European Organization for Research and Treatment of Cancer. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 69(11):4700-7
69. Innominato PF, Levi FA, Bjarnason GA (2010) Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 62(9-10):979-1001
70. Innominato PF, Giacchetti S, Moreau T et al (2011) Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil- leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int 7:586-600
71. Innominato PF, Giacchetti S, Bjarnason GA et al (2012) Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer Apr 5. doi:10.1002/ijc.27574
72. Kalsbeek A, Fliers E (2013) Daily regulation of hormone profiles. In: Kramer A, Merrow M (eds) Circadian clocks, vol 217, Handbook of experimental pharmacology. Springer, Heidelberg
73. Kang B, Li YY, Chang X et al (2008) Modeling the effects of cell cycle M-phase transcriptional inhibition on circadian oscillation. PLoS Comput Biol. doi:10.1371/journal.pcbi.1000019
74. Kang TH, Lindsey-Boltz LA, Reardon JT et al (2010) Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci USA 107(11):4890-5
75. Kerkhof GA, Van Dongen HP (1996) Morning-type and evening-type individuals differ in the phase position of their endogenous circadian oscillator. Neurosci Lett 218:153-6
76. Khapre RV, Samsa WE, Kondratov RV (2010) Circadian regulation of cell cycle: molecular connections between aging and the circadian clock. Ann Med 42(6):404-15
77. Ko CH, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15(suppl 2):R271-7
78. Koyanagi S, Kuramoto Y, Nakagawa H (2003) A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 63(21):7277-83
79. Krauchi K (2002) How is the circadian rhythm of core body temperature regulated? Clin Auton Res 12(3):147-9
80. Lee JH, Sancar A (2011) Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. Proc Natl Acad Sci USA 108(26):10668-72
81. Leloup JC, Goldbeter A (2003) Toward a detailed computational model for the mammalian circadian clock. Proc Natl Acad Sci USA 100(12):7051-6
82. Leloup JC, Gonze D, Goldbeter A (1999) Limit cycle models for circadian rhythms based on transcriptional regulation in Drosophila and Neurospora. J Biol Rhythms 6:433-448
83. Levi F (2012) Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC). In: Abstract 2012Gastrointestinal cancers symposium - Category: Cancers of the colon and rectum - Translational research, San Francisco, CA, USA, 19-21 Jan 2012
84. Levi F, Okyar A (2011) Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv 8(12):1535-41
85. Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593-628
86. Levi F, Altinok A, Clairambault J et al (2008) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos Trans A Math Phys Eng Sci 366:3575-98
87. Levi F, Benavides M, Chevelle C et al (1990) Chemotherapy of advanced ovarian cancer with 40-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 8(4):705-14
88. Levi F, Misset JL, Brienza S et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69(4):893-900
89. Levi F, Perpoint B, Garufi C et al (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A(9):1280-4
90. Levi FA, Zidani R, Vannetzel JM et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86(21):1608-17
91. Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350(9079):681-6
92. Levi F, Filipski E, Iurisci I et al (2007a) Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 72:465-75
93. Levi F, Focan C, Karaboue A et al (2007b) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59(9-10):1015-35
94. Levi F, Okyar A, Dulong S et al (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377-421
95. Li XM, Vincenti M, Levi F (2002) Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol Int 19(1):43-55
96. Li XM, Delaunay F, Dulong S et al (2010) Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res 70(8):3351-60
97. Martin C, Dutertre-Catella H, Radionoff Met al (2003) Effect of age and photoperiodic conditions on metabolism and oxidative stress related markers at different circadian stages in rat liver and kidney. Life Sci 73(3):327-35
98. Mazzoccoli G, Panza A, Valvano MR et al (2011) Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int 28(10):841-51
99. Merrow M, Dragovic Z, Tan Y et al (2003) Combining theoretical and experimental approaches to understand the circadian clock. Chronobiol Int 20(4):559-575
100. Miyamoto N, Izumi H, Noguchi T et al (2008) Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 283(26):18218-26
101. Mormont MC, Levi F (1997) Circadian-system alterations during cancer processes: a review. Int J Cancer 70(2):241-7
102. Mormont MC, Hecquet B, Bogdan A et al (1998) Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 78(4):421-4
103. Mormont MC, Waterhouse J, Bleuzen P et al (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6(8):3038-45
104. Mormont MC, Langouet AM, Claustrat B et al (2002) Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. Chronobiol Int 19(1):141-55
105. Murakami Y, Higashi Y, Matsunaga N (2008) Circadian clock - controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology 135:1636-1644
106. O'Neill JS, Reddy AB (2011) Circadian clocks in human red blood cells. Nature 469(7331):498-503
107. O'Neill JS, van Ooijen G, Dixon LE et al (2011) Circadian rhythms persist without transcription in a eukaryote. Nature 469(7331):554-8
108. O'Neill JS, Maywood ES, Hastings MH (2013) Cellular mechanisms of circadian pacemaking: beyond transcriptional loops. In: Kramer A, Merrow M (eds) Circadian clocks, vol 217, Handbook of experimental pharmacology. Springer, Heidelberg
109. Oklejewicz M, Destici E, Tamanini F et al (2008) Phase resetting of the mammalian circadian clock by DNA damage. Curr Biol 18(4):286-91
110. Okyar A, Piccolo E, Ahowesso C et al (2011) Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One 6(6):e20393
111. Ortiz-Tudela E, Martinez-Nicolas A, Campos M (2010) A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput Biol 6(11):e1000996
112. Ortiz-Tudela E, Innominato PF, Iurisci I et al (2011) Chemotherapy-induced disruption of circadian system in cancer patients. In: XII Congress of the European Biological Rhythms Society, Oxford, UK, 20-26 Aug 2011
113. Oshima T, Takenoshita S, Akaike M et al (2011) Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep 25(5):1439-46. doi:10.3892/ or.2011.1207
114. Otalora BB, Madrid JA, Alvarez N et al (2008) Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. J Pineal Res 44(3):307-15
115. Paine SJ, Gander PH, Travier (2006) The epidemiology of morningness/eveningness: influence of age, gender, ethnicity, and socioeconomic factors in adults (30-49 years). J Biol Rhythms 21(1):68-76
116. Panda S, Hogenesch JB, Kay SA (2002) Circadian rhythms from flies to human. Nature 417(6886):329-35
117. Qvortrup C, Jensen BV, Fokstuen T et al (2010) A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Ann Oncol 21(1):87-91
118. Rahn DA 3rd, Ray DK, Schlesinger DJ et al (2011) Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? Cancer 117(2):414-20
119. Relogio A, Westermark PO, Wallach T et al (2011) Tuning the mammalian circadian clock: robust synergy of two loops. PLoS Comput Biol 7(12):e1002309
120. Rivard GE, Infante-Rivard C, Dresse MF et al (1993) Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival. Chronobiol Int 10(3):201-4
121. Roenneberg T, Kuehnle T, Pramstaller PP et al (2004) A marker for the end of adolescence. Curr Biol 14(24):R1038-9
122. Roenneberg T, Kuehnle T, JudaMet al (2007a) Epidemiology of the human circadian clock. Sleep Med Rev 11(6):429-38
123. Roenneberg T, Kumar CJ, Merrow M (2007b) The human circadian clock entrains to sun time. Curr Biol 17(2):R44-5
124. Roenneberg T, Kantermann T, Juda M, Vetter C, Allebrandt KV (2013) Light and the human circadian clock. In: Kramer A, Merrow M (eds) Circadian clocks, vol 217, Handbook of experimental pharmacology. Springer, Heidelberg
125. Sarabia JA, Rol MA, Mendiola P et al (2008) Circadian rhythm of wrist temperature in normalliving subjects. A candidate of new index of the circadian system. Physiol Behav 95(4):570-80
126. Savard J, Liu L, Natarajan L et al (2009) Breast cancer patients have progressively impaired sleepwake activity rhythms during chemotherapy. Sleep 32(9):1155-60
127. Scully CG, Karaboue A, Liu WM et al (2011) Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients. Interface Focus 1:48-60
128. Seely D, Wu P, Fritz H et al (2011) Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther 11(4):293-303
129. Sephton SE, Sapolsky RM, Kraemer HC et al (2000) Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 92(12):994-1000
130. Smaaland R, Sothern RB, Laerum OD et al (2002) Rhythms in human bone marrow and blood cells. Chronobiol Int 19(1):101-27
131. Spies CM, Cutolo M, Straub RH et al (2011) Prednisone chronotherapy. Clin Exp Rheumatol 29(5 Suppl 68):S42-5
132. Storch KF, Lipan O, Leykin I et al (2002) Extensive and divergent circadian gene expression in liver and heart. Nature 417(6884):78-83
133. Tampellini M, Filipski E, Liu XH et al (1998) Docetaxel chronopharmacology in mice. Cancer Res 58(17):3896-904
134. Tokunaga H, Takebayashi Y, Utsunomiya H et al (2008) Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand 87(10):1060-70
135. Touitou Y, Auzeby A, Camus F et al (2009) Daily profiles of salivary and urinary melatonin and steroids in healthy prepubertal boys. J Pediatr Endocrinol Metab 22(11):1009-15
136. Tozer TN, Rowland M (2006) Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy. Lippincott, Baltimore, MD
137. Tsukamoto Y, Kato Y, Ura M et al (2001) A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 18(8):1190-202
138. Van Ryckeghem F, Van Belle S (2010) Management of chemotherapy-induced nausea and vomiting. Acta Clin Belg 65(5):305-10
139. Van Someren EJ, Nagtegaal E (2007) Improving melatonin circadian phase estimates. Sleep Med 8:590-601
140. Vassal G, Challine D, Koscielny S et al (1993) Chronopharmacology of high-dose busulfan in children. Cancer Res 53(7):1534-7
141. Veldhuis JD, Iranmanesh A, Johnson ML et al (1990) Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol Metab 71:452-63
142. Vink JM, Groot AS, Kerkhof GA et al (2001) Genetic analysis of morningness and eveningness. Chronobiol Int 18:809-22
143. Wang J, Huang Y (2007) Pharmacogenomics of sex difference in chemotherapeutic toxicity. Curr Drug Discov Technol 4(1):59-68
144. Waterhouse J, Drust B, Weinert D et al (2005) The circadian rhythm of core temperature: origin and some implications for exercise performance. Chronobiol Int 22(2):207-25
145. Weis J (2011) Cancer-related fatigue: prevalence, assessment and treatment strategies. Expert Rev Pharmacoecon Outcomes Res 11(4):441-6
146. Wood PA, Yang X, Taber A et al (2008) Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res 6(11):1786-93
147. Yeh KT, Yang MY, Liu TC et al (2005) Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 206(1):111-20
148. Yi C, Mu L, de la Longrais IA et al (2010) The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat 120(3):663-9
149. Zhou F, He X, Liu H et al (2011) Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer. doi:10.1002/cncr.26348
150. Zhu Y, Leaderer D, Guss C et al (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 120(2):432-5
151. Zhu Y, Stevens RG, Leaderer D et al (2008) Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 107(3):421-5